Stocks Screener

Search any stock or ticker

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

How This Company Makes Money

Dividend Analysis AARTIPHARM

Max Ratio

Dividend Yield

0.93 %

5Y Dividend Growth

0.00 %

Consecutive Years

1 year

5Y Average Payout Ratio

14.59 %

Dividend History AARTIPHARM

1 year
3 years
5 years
10 years
15 years
11/21/2021 - 11/28/2021
Forward Annual Dividend Yield 0.93 %
Consecutive Years 1
Forward Annual Dividend 6.50 INR
Consistent Years 1
Dividend CAGR 3Y
Continuous Dividends 2
Dividend CAGR 5Y
Payout Ratio TTM 12.97 %
Dividend CAGR 10Y
Ex Dividend Date 02/16/2026

The 5 Pillars Formula Checklist

The Five-Pillar Secret Formula Checklist is our simple, proven way to separate strong, lasting businesses from the rest. We look at five key pillars—sales growth, profit growth, Net Income, dividend safety, and debt levels. Together with Financial Score, they tell us if a company can keep growing, stay financially solid, and reliably pay dividends for decades.

Sales Growth AARTIPHARM

Sales Growth – The Foundation of a Strong Business. Consistent revenue growth over the past 10-15 years is a key sign of a thriving company. It shows that demand for its products and services is increasing, allowing it to expand operations, gain market share, and invest in future growth.
1 year
3 years
5 years
10 years

Profit Growth / Profit Margin AARTIPHARM

The Fuel for Company Growth. Revenue alone isn’t enough—what truly matters is how efficiently a company turns that revenue into consistent, growing profits. Profitability is the foundation of sustainable growth and long-term financial strength.
1 year
3 years
5 years
10 years

Net Income AARTIPHARM

The True Measure of Financial Strength. Net income is what remains after all expenses, taxes, and costs. This is the company’s real earning power.
1 year
3 years
5 years
10 years

Payout Ratio TTM AARTIPHARM

Dividend Payout Safety – Protecting Your Passive Income. A high dividend yield is meaningless if the company can’t afford to sustain it. We evaluate payout ratios to ensure the company is not overextending itself. The best companies have a balanced approach—paying generous dividends while still reinvesting in future growth. Dividend safety is crucial for long-term income stability.
1 year
3 years
5 years
10 years
15 years
11/21/2021 - 11/28/2021

Debt Ratio AARTIPHARM

Debt Burden – Avoiding Financial Traps. Too much debt can cripple a company, even if its revenues and profits look great. We analyze how well a company manages its liabilities, ensuring that debt levels are under control.
1 year
3 years
5 years
10 years
11/21/2021 - 11/28/2021

Full Financial Performance

See how the company makes money over time—revenue, profits, dividends, and more. The charts on the right give you a quick view of growth trends so you can instantly spot consistency or red flags.

Aarti Pharmalabs Limited AARTIPHARM

1 year
3 years
5 years
10 years
Results 2019 Dynamics
* The data for this period has not yet been published

Bottom Line

Valuation Check

Shows if a stock is priced fairly by looking at peers and the company’s own history — a quick way to see if it’s a bargain or overpriced.

Value vs Itself AARTIPHARM

P/E shows how many dollars investors pay in the stock price for each $1 of profit the company earns per share. Today’s P/E is compared with the company’s 10-year average. If the ratio is above that norm, you’re paying up for each dollar of profit. If it’s below, you’re getting more earnings for less.
1 year
3 years
5 years
10 years
11/21/2021 - 11/28/2021
Trailing PE 38.06
Forward PE
Enterprise Value Revenue 3.98
Price Sales TTM 3.61
Enterprise Value EBITDA 18.87
Price Book MRQ 3.06

Aarti Pharmalabs Limited

AARTIPHARM
Current price
702.35 INR +4.5 INR (+0.64%)
Last closed 697.95 INR
ISIN INE0LRU01027
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange National Stock Exchange of India
Capitalization 65 853 870 447 INR
Yield for 12 month -24.85 %
1Y
3Y
5Y
10Y
15Y
AARTIPHARM
11/21/2021 - 11/28/2021

Advanced Highlights

Current Year

+18 251 578 799 INR

Last Year

+21 217 186 409 INR

Current Quarter

+5 844 742 496 INR

Last Quarter

+4 336 305 850 INR

Current Year

+9 877 030 325 INR

Last Year

+9 902 981 662 INR

Current Quarter

+3 005 634 003 INR

Last Quarter

+2 604 325 284 INR
EBITDA 4 036 817 933 INR
Operating Margin TTM 17.50 %
Price to Earnings 38.06
Return On Assets TTM 5.83 %
PEG Ratio
Return On Equity TTM 8.49 %
Wall Street Target Price 71 442.08 INR
Revenue TTM 18 251 579 634 INR
Book Value 235.01 INR
Revenue Per Share TTM 201.31 INR
Dividend Share 3.51 INR
Quarterly Revenue Growth YOY 3.30 %
Dividend Yield 0.93 %
Gross Profit TTM 9 877 030 348 INR
Earnings per share 19.08 INR
Diluted Eps TTM 19.08 INR
Most Recent Quarter I 2026
Quarterly Earnings Growth YOY -30.80 %
Profit Margin 9.60 %
Price to Free Cash Flow TTM -34.17

Technical Indicators AARTIPHARM

For 52 Weeks

586.84 INR 968.36 INR
50 Day MA 688.51 INR
Shares Short Prior Month
200 Day MA 727.00 INR
Short Ratio
Shares Short
Short Percent